A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Trial Profile

A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Temozolomide (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Jul 2016 Planned number of patients changed from 30 to 20.
    • 13 Jul 2016 Planned End Date changed from 1 Dec 2014 to 1 Jul 2019.
    • 13 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top